Roche commits $75M upfront for Simcere blood-cancer drug rights
Roche committed $75 million upfront for global rights to Simcere Pharmaceutical’s experimental blood-cancer drug SIM0660, with exclusive development, manufacturing and commercialization rights.
Roche (RHHBY), the Swiss pharmaceuticals and diagnostics giant, committed $75 million upfront for global rights to Simcere Pharmaceutical's experimental blood-cancer drug SIM0660.
Its U.S.-quoted shares fell to $53.55 Tuesday.The agreement hands Roche exclusive development, manufacturing and commer…